12 October 2021: Original Paper
Prognostic Role of Serum Albumin Level in Patients with Lymphoma Undergoing Autologous Stem Cell Transplantation
Chengxin Luo 12CDE , Qingrong Li 12B , Xi Li 3B , Guixian Wu 12B , Xiangtao Huang 12B , Yali Zhang 12B , Yanni Ma 12B , Mingling Xie 12B , Yanni Sun 12B , Yarui Huang 12B , Zhen Huang 12B , Shuangnian Xu 12AEG* , Jieping Chen 12AEG*DOI: 10.12659/AOT.933365
Ann Transplant 2021; 26:e933365
Table 5 Results of univariate and multivariate Cox regression analyses for overall survival in the B-cell non-Hodgkin lymphoma subgroup.
| Characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95%CI) | P | HR (95%CI) | P | |
| Male | 1.43 (0.49–4.10) | 0.512 | ||
| Age >60 | 2.75 (0.89–8.56) | 0.080 | ||
| BMI | 0.04 (0.00–74.49) | 0.408 | ||
| ECOG PS 2–3 | 1.13 (0.42–3.03) | 0.810 | ||
| Ann Arbor stage III–IV | 1.79 (0.78–4.11) | 0.169 | ||
| B symptoms | 0.49 (0.14–1.73) | 0.270 | ||
| IPI risk | ||||
| Low | 1.00 | |||
| Low-intermediate | 0.89 (0.22–3.56) | 0.869 | ||
| High-intermediate | 1.98 (0.49–7.93) | 0.335 | ||
| High | 2.94 (0.72–11.93) | 0.132 | ||
| LDH elevation (>240 U/L) | 3.29 (1.19–9.09) | 0.021* | 2.83 (1.003–8.01) | 0.049* |
| Bone marrow involvement | 4.84 (1.55–15.11) | 0.007* | ||
| Prior regimens | ||||
| 1.00 | ||||
| 5–10 | 1.16 (0.23–5.98) | 0.859 | ||
| ≥10 | 1.51 (0.52–4.42) | 0.451 | ||
| Rituximab induction | 1.66 (0.62–4.43) | 0.312 | ||
| PR or NR | 1.84 (0.68–4.94) | 0.227 | ||
| Disease duration | 0.99 (0.96–1.02) | 0.564 | ||
| Albumin | 2.79 (0.97–8.08) | 0.058 | ||
| TP | 4.65 (1.72–12.59) | 0.002* | 3.74 (1.35–10.38) | 0.011* |
| Globulin level | 0.90 (0.81–1.01) | 0.073 | ||
| Albumin/globulin ratio | 2.13 (0.55–8.27) | 0.275 | ||
| Conditioning regimen | ||||
| BEAM | 1.00 | |||
| BEAC | 1.40 (0.13–15.49) | 0.782 | ||
| CBV | 3.73 (0.41–27.84) | 0.259 | ||
| CHOP-like | 3.24 (0.38–27.74) | 0.283 | ||
| Dose of infused mononuclear cells | 0.87 (0.67–1.13) | 0.295 | ||
| Maintenance therapy | 0.41 (0.12–1.47) | 0.173 | ||
| * B-NHL – B-cell non-Hodgkin lymphoma; BEAC – carmustine, etoposide, cytarabine, and cyclophosphamide; BEAM – carmustine, etoposide, cytarabine, and melphalan; BMI – body mass index; CHOP – cyclophosphamide, anthracycline, vincristine, and prednisone; CBV – cyclophosphamide, carmustine, and etoposide; CR – complete remission; ECOG PS – Eastern Cooperative Oncology Group performance status; HL – Hodgkin lymphoma; HR – hazard ratio; IPI – international prognostic index; LDH – lactate dehydrogenase; NHL – non-Hodgkin lymphoma; NR – no response; OS – overall survival; PR – partial remission; TP – total protein. | ||||